{"id":"insulin-lispro-aabc","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":{"setId":"c5a056e2-b568-4ca6-9ed8-79c010942d00","title":"LYUMJEV (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV JUNIOR KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV TEMPO PEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION [ELI LILLY AND COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin Lispro-aabc is a biosynthetic insulin analog engineered with amino acid substitutions (aabc denotes the specific modifications) that allow faster absorption and onset of action compared to human insulin. It mimics endogenous insulin by binding to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production. The rapid kinetics make it suitable for mealtime insulin therapy in diabetes management.","oneSentence":"Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:20.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07090824","phase":"PHASE1","title":"Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-10-28","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT06370715","phase":"PHASE4","title":"A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-18","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT05325294","phase":"NA","title":"Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2022-05-05","conditions":"Type 1 Diabetes","enrollment":244}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ABDOMINAL PAIN UPPER"},{"count":2,"reaction":"INJECTION SITE PAIN"},{"count":1,"reaction":"ABDOMINAL ABSCESS"},{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"ABDOMINAL HERNIA"},{"count":1,"reaction":"ACUTE CHOLECYSTITIS NECROTIC"},{"count":1,"reaction":"ARTHRITIS"},{"count":1,"reaction":"ARTHROPATHY"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"DEATH"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY900014"],"phase":"marketed","status":"active","brandName":"Insulin Lispro-aabc","genericName":"Insulin Lispro-aabc","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}